期刊文献+

椎体弥漫大B细胞淋巴瘤颅内侵犯一例 被引量:3

A case of centrum diffuse large B-cell lymphoma with intracranial invading
原文传递
导出
摘要 患者女性,64岁。2015年12月20日因患非霍奇金淋巴瘤13个月,头晕、恶心3 d入我院。于2014年11月因颈部疼痛伴左侧肩胛部及左上肢麻木,行颈椎CT及磁共振成像检查,多考虑脊柱肿瘤;全身骨扫描提示:全身多发肿瘤骨转移。于2015年2月3日在腰部麻醉下行前入路C6病椎体全切术及植骨融合术,C6椎体病理诊断为恶性肿瘤,考虑转移;免疫组织化学示:瘤细胞CD30-,CD138-,CD56-,EMA-,CgA-,GFAP-, CD3-,Syn-,S100-,CK8/18-,PAX5-,CKP-,Vimentin-,CD79a+/-,CD10+/-,CD68-,CD34-,OLig2-,Ki-67+/-。复旦大学会诊提示:C6椎体恶性肿瘤,倾向为弥漫大B细胞淋巴瘤(DLBCL),免疫组织化学示:AE1/AE3-,CAM5.2,CD10-,CK-,CK7-,CK8-,Ki-67+(约60%),P504S-,PAX8-,S100-,Vimentin+,CD20+,CD3-,CD79a-, c-myc-,PAX5-。术后患者左上肢仍感麻木疼痛,并出现右侧髋部及右下肢疼痛。于2015年4月行正电子发射计算机断层显像(PET-CT)提示:全身多发淋巴结及全身多发骨骼脱氧葡萄糖(FDG)代谢异常增高,考虑:淋巴瘤或其他恶性肿瘤并全身广泛转移不能完全排除。骨髓检查未见淋巴瘤细胞浸润。诊断为DLBCL(第6颈椎)。先后予CHOP方案化疗1个疗程,R-CHOP方案化疗6个疗程。治疗后患者不适症状均缓解,评估治疗有效。
出处 《肿瘤研究与临床》 CAS 2017年第1期58-59,共2页 Cancer Research and Clinic
基金 甘肃省自然科学基金(145RJZA151)
  • 相关文献

参考文献3

二级参考文献25

  • 1张登晓.中枢神经系统非霍奇金淋巴瘤2例[J].白血病.淋巴瘤,2005,14(6):384-384. 被引量:1
  • 2Chihara D, Oki Y, Matsuo K, et al. Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: analyses with competing risk regression model. Leuk Lymphoma, 2011,52: 2270-2275.
  • 3Bernstein SH, Unger JM, Leblanc M, et al. Natural history of CNS relapse in patients with aggressive non-Hodgkin lymphoma: a 20-year follow up analysis of SWOG 8516-The Southwest Oncology Group. J Clin Oncol, 2009, 27:114-119.
  • 4Villa D, Connors JM, Shenkier TN, et al. Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy. Ann Oncol, 2010, 21: 1046-1052.
  • 5Papageorgiou SG, Diamantopoulos P, Levidou G, et al. Isolated central nervous system relapses in primary mediastinal large B-cell lymphoma after CHOP-like chemotherapy with or without rituximab. Hematol Oncol, 2012 May 18. doi: 10.1002/hon.2012.
  • 6Tai WM, Chung J, Tang PL, et al. Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre- and post- rituximab. Ann Hematol, 2011, 90:809-818.
  • 7Hegde U, Filie A, Little RF, et al. High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology. Blood, 2005, 105: 496-502.
  • 8Kridel R, Dietrich PY. Prevention of CNS relapse in diffuse large B- cell lymphoma. Lancet Oncol, 2011, 12: 1258-1266.
  • 9Kumar A, Vanderplas A, Lacasce AS, et al. Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: findings from a large national database. Cancer, 2012, 118: 2944-2951.
  • 10Baraniskin A, Deckert M, Schulte-Ahedorneburg G, et al. Current strategies in the diagnosis of diffuse large B-cell lymphoma of the central nervous system. Br J Haematol, 2012, 156: 421-432.

共引文献4

同被引文献28

引证文献3

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部